非诺贝特治疗腹主动脉瘤(FAME):一项随机对照试验的研究方案
FAME是一项多中心、随机、双盲、安慰剂对照临床试验,旨在评估口服非诺贝特对开放腹主动脉瘤修复术患者瘤壁关键病理标志物的影响。42例择期开放腹主动脉瘤修复术患者随机接受每日145 mg非诺贝特或相同安慰剂,术前至少2周。主要结局为瘤壁巨噬细胞数量、骨桥蛋白浓度及血清骨桥蛋白浓度。
要点
- FAME试验评估非诺贝特对腹主动脉瘤瘤壁病理标志物的影响。
- 42例择期开放腹主动脉瘤修复术患者随机接受非诺贝特145 mg/日或安慰剂至少2周。
- 主要结局为瘤壁巨噬细胞数量、骨桥蛋白浓度及血清骨桥蛋白浓度。
核心结论
- 目前尚无公认的药物治疗可限制腹主动脉瘤进展,FAME试验旨在评估非诺贝特改变腹主动脉瘤病理组织标志物的能力。
研究设计与样本
- FAME是一项多中心、随机、双盲、安慰剂对照临床试验,共42例计划行择期开放腹主动脉瘤修复术的参与者随机接受每日145 mg非诺贝特或相同安慰剂,术前至少2周。
关键数值与推荐
- 主要结局指标为腹主动脉瘤壁内巨噬细胞数量和骨桥蛋白浓度以及血清骨桥蛋白浓度。
- 次要结局指标包括腹主动脉瘤壁、主动脉周围脂肪和壁内血栓中的基质金属蛋白酶和促炎细胞因子水平以及循环腹主动脉瘤生物标志物浓度。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Abdominal aortic aneurysm (AAA) is a slowly progressive destructive process of the main abdominal artery. Experimental studies indicate that fibrates exert beneficial effects on AAAs by mechanisms involving both serum lipid modification and favourable changes to the AAA wall. METHODS/DESIGN: Fenofibrate in the management of AbdoMinal aortic anEurysm (FAME) is a multicentre, randomised, double-blind, placebo-controlled clinical trial to assess the effect of orally administered therapy with fenofibrate on key pathological markers of AAA in patients undergoing open AAA repair. A total of 42 participants scheduled for an elective open AAA repair will be randomly assigned to either 145 mg of fenofibrate per day or identical placebo for a minimum period of 2 weeks prior to surgery. Primary outcome measures will be macrophage number and osteopontin (OPN) concentration within the AAA wall as well as serum concentrations of OPN. Secondary outcome measures will include levels of matrix metalloproteinases and proinflammatory cytokines within the AAA wall, periaortic fat and intramural thrombus and circulating concentrations of AAA biomarkers. DISCUSSION: At present, there is no recognised medical therapy to limit AAA progression. The FAME trial aims to assess the ability of fenofibrate to alter tissue markers of AAA pathology. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry, ACTRN12612001226897 . Registered on 20 November 2012.
引用
- Rowbotham SE, Cavaye D, Jaeggi R, et al. Fenofibrate in the management of AbdoMinal aortic anEurysm (FAME): study protocol for a randomised controlled trial. Trials. 2017. PMID: 28049491. doi:10.1186/s13063-016-1752-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。